Sayeh Lavasani1,2, Rowan T Chlebowski3, Ross L Prentice4, Ikuko Kato2,5, Jean Wactawski-Wende6, Karen C Johnson7, Alicia Young4, Rebecca Rodabough4, F Allan Hubbell8, Ali Mahinbakht9, Michael S Simon1,2. 1. Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, Michigan. 2. Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 3. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California. 4. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Department of Pathology, Wayne State University, Detroit, Michigan. 6. Department of Social and Preventive Medicine, University at Buffalo, Buffalo, New York. 7. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 8. Department of Medicine, University of California Irvine, Irvine, California. 9. University of Liverpool, Liverpool, United Kingdom.
Abstract
BACKGROUND: The preponderance of observational studies describe an association between the use of estrogen alone and a lower incidence of colorectal cancer. In contrast, no difference in the incidence of colorectal cancer was seen in the Women's Health Initiative (WHI) randomized, placebo-controlled trial with estrogen alone after a mean intervention of 7.1 years and cumulative follow-up of 13.2 years. This study extends these findings by providing detailed analyses of the effects of estrogen alone on the histology, grade, and stage of colorectal cancer, relevant subgroups, and deaths from and after colorectal cancer. METHODS: The WHI study was a randomized, double-blind, placebo-controlled trial involving 10,739 postmenopausal women with prior hysterectomy. Participants were assigned to conjugated equine estrogen at 0.625 mg/d (n = 5279) or a matching placebo (n = 5409). Rates of colorectal cancer diagnoses and deaths from and after colorectal cancer were assessed throughout the study. RESULTS:Colorectal cancer rates in the estrogen-alone and placebo groups were comparable: 0.14% and 0.12% per year, respectively (hazard ratio [HR], 1.13; 95% confidence interval [CI], 0.83-1.58; P = .43). Bowel screening examinations were comparable between the 2 groups throughout the study. The grade, stage, and location of colorectal cancer did not differ between the randomization groups. There were more colorectal cancer deaths in the estrogen-alone group (34 [0.05%] vs 24 [0.03%]; HR, 1.46, 95% CI, 0.86-2.46; P = .16), but the difference was not statistically significant. The colorectal cancer incidence was higher for participants with a history of colon polyp removal in the estrogen-alone group (0.23% vs 0.02%; HR, 13.47; nominal 95% CI, 1.76-103.0; P < .001). CONCLUSIONS: The use of estrogen alone in postmenopausal women with prior hysterectomy does not influence the incidence of colorectal cancer or deaths from or after colorectal cancer. A possibly higher risk of colorectal cancer in women with prior colon polyp removal who useestrogen alone requires confirmation.
RCT Entities:
BACKGROUND: The preponderance of observational studies describe an association between the use of estrogen alone and a lower incidence of colorectal cancer. In contrast, no difference in the incidence of colorectal cancer was seen in the Women's Health Initiative (WHI) randomized, placebo-controlled trial with estrogen alone after a mean intervention of 7.1 years and cumulative follow-up of 13.2 years. This study extends these findings by providing detailed analyses of the effects of estrogen alone on the histology, grade, and stage of colorectal cancer, relevant subgroups, and deaths from and after colorectal cancer. METHODS: The WHI study was a randomized, double-blind, placebo-controlled trial involving 10,739 postmenopausal women with prior hysterectomy. Participants were assigned to conjugated equine estrogen at 0.625 mg/d (n = 5279) or a matching placebo (n = 5409). Rates of colorectal cancer diagnoses and deaths from and after colorectal cancer were assessed throughout the study. RESULTS:Colorectal cancer rates in the estrogen-alone and placebo groups were comparable: 0.14% and 0.12% per year, respectively (hazard ratio [HR], 1.13; 95% confidence interval [CI], 0.83-1.58; P = .43). Bowel screening examinations were comparable between the 2 groups throughout the study. The grade, stage, and location of colorectal cancer did not differ between the randomization groups. There were more colorectal cancer deaths in the estrogen-alone group (34 [0.05%] vs 24 [0.03%]; HR, 1.46, 95% CI, 0.86-2.46; P = .16), but the difference was not statistically significant. The colorectal cancer incidence was higher for participants with a history of colon polyp removal in the estrogen-alone group (0.23% vs 0.02%; HR, 13.47; nominal 95% CI, 1.76-103.0; P < .001). CONCLUSIONS: The use of estrogen alone in postmenopausal women with prior hysterectomy does not influence the incidence of colorectal cancer or deaths from or after colorectal cancer. A possibly higher risk of colorectal cancer in women with prior colon polyp removal who use estrogen alone requires confirmation.
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810
Authors: Kara A Michels; Ashley M Geczik; Doug C Bauer; Louise A Brinton; Diana S M Buist; Jane A Cauley; Cher M Dallal; Roni T Falk; Trisha F Hue; James V Lacey; Andrea Z LaCroix; Jeffrey A Tice; Xia Xu; Britton Trabert Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04-07 Impact factor: 4.090
Authors: Sonja Neumeyer; Barbara L Banbury; Volker Arndt; Sonja I Berndt; Stephane Bezieau; Stephanie A Bien; Dan D Buchanan; Katja Butterbach; Bette J Caan; Peter T Campbell; Graham Casey; Andrew T Chan; Stephen J Chanock; James Y Dai; Steven Gallinger; Edward L Giovannucci; Graham G Giles; William M Grady; Jochen Hampe; Michael Hoffmeister; John L Hopper; Li Hsu; Mark A Jenkins; Amit Joshi; Susanna C Larsson; Loic Le Marchand; Annika Lindblom; Victor Moreno; Mathieu Lemire; Li Li; Yi Lin; Kenneth Offit; Polly A Newcomb; Paul D Pharaoh; John D Potter; Lihong Qi; Gad Rennert; Clemens Schafmayer; Robert E Schoen; Martha L Slattery; Mingyang Song; Cornelia M Ulrich; Aung K Win; Emily White; Alicja Wolk; Michael O Woods; Anna H Wu; Stephen B Gruber; Hermann Brenner; Ulrike Peters; Jenny Chang-Claude Journal: Br J Cancer Date: 2018-05-24 Impact factor: 7.640
Authors: Rosa Schmuck; Michael Gerken; Eva-Maria Teegen; Isabell Krebs; Monika Klinkhammer-Schalke; Felix Aigner; Johann Pratschke; Beate Rau; Stefan Benz Journal: Langenbecks Arch Surg Date: 2020-01-31 Impact factor: 3.445
Authors: Su Yon Jung; Thomas Rohan; Howard Strickler; Jennifer Bea; Zuo-Feng Zhang; Gloria Ho; Carolyn Crandall Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240